CHARLES RIVER LABORATORIES INTERNA (CRL)
Sector: Health Care
Sector: Health Care
CHARLES RIVER LABORATORIES INTERNA - Executive Compensation
Corporate Executive Vice President, Chief Financial Officer
Executive Compensation
Flavia H. Pease serves as the Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories International, a leading provider of essential products and services to help pharmaceutical and biotechnology companies, government agencies, and academic institutions accelerate their research and drug development efforts. In her role, Flavia is responsible for overseeing the company's global financial operations, including financial planning and analysis, accounting, tax, treasury, and investor relations. Her strategic vision and financial acumen have been instrumental in driving Charles River Laboratories' growth and success in the highly competitive life sciences industry. Prior to joining Charles River Laboratories, Flavia held several senior financial leadership positions at prominent companies in the healthcare and life sciences sectors. She has a proven track record of successfully managing complex financial operations, implementing effective cost-saving measures, and driving profitability. Flavia's extensive experience and deep understanding of the industry have enabled her to make significant contributions to Charles River Laboratories' financial strategy and performance. Under her leadership, the company has achieved strong financial results, expanded its global presence, and strengthened its position as a trusted partner in the life sciences community. Flavia is a respected leader in the financial and life sciences communities, known for her strategic thinking, collaborative approach, and commitment to excellence. She holds a bachelor's degree in accounting from a top-tier university and is a certified public accountant. Flavia's dedication to driving innovation and growth at Charles River Laboratories, combined with her passion for advancing scientific research and improving patient outcomes, make her an invaluable asset to the company and the industry as a whole.